Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Medulloblastoma 1Ependymoma 1

Interventions

Temozolomide 26Magnetic Resonance Spectroscopy 19Etoposide 12Cyclophosphamide 12Radiotherapy 11Bevacizumab 10Filgrastim 9Biopsy 8Carboplatin 7X-Rays 6Thiotepa 6Specimen Handling 6Phantoms, Imaging 6Cisplatin 6Carmustine 6Nuclear Medicine Department, Hospital 5Nivolumab 5Irinotecan 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 5sargramostim 4Radiation 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4olaparib 3etoposide phosphate 3Vincristine 3Surveys and Questionnaires 3Lapatinib 3Gadolinium DTPA 3Azacitidine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ependymoma × Antiemetics × CNS × Clear all
NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Pediatric Brain Tumor Consortium

Phase 2 Active not recruiting
62 enrolled
CNS

Ependymoma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡